{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:18:54Z","timestamp":1792149534566,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Graves\u2019 ophthalmopathy (GO) is an autoimmune disease that affects orbital soft tissues and represents the most common extrathyroidal manifestation of Graves\u2019 disease (GD). The European Group of Graves\u2019 Ophthalmopathy (EUGOGO) has attempted to shed light on the European epidemiological picture of GO, suggesting that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation. There are no studies that focus this issue on the population of our area; we aimed to evaluate the trend of GO clinical presentation in our outpatient clinic through an observation period of 10\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared 55 consecutive patients, 11 males (F) and 44 females (M), who came to our observation from January 2005 to December 2006 [Group 1 (G1)], with 56 patients, 15 males, and 41 females, who were referred to us from 2015 to 2016 [Group 2 (G2)]. We studied the following putative predictors of GO presentation and severity: thyroid function, smoking, diabetes, hypercholesterolemia, time from GO diagnosis to referral to our thyroid centre (TGOD), sex and age.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>GO severity was significantly reduced in G2 vs. G1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). TGOD\u2009\u2265\u20093\u00a0months was related to clinical characteristics of GO (severity and Clinical Activity Score\u2009\u2265\u20094) and was an independent predictor of GO severity (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). The other variables evaluated had no independent effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found that GO severity at presentation was significantly reduced over a ten-year observation period (2005\u20132006 vs. 2015\u20132016) in GO patients referred to our tertiary thyroid centre. TGOD\u2009\u2265\u20093\u00a0months was an independent predictor of GO severity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02332-3","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T09:01:22Z","timestamp":1710493282000},"page":"2177-2184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Temporal trends in the clinical presentation of Graves\u2019 orbitopathy: a single\u2013center retrospective study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-9271","authenticated-orcid":false,"given":"R.","family":"Le Moli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Naselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Lo","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2332_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Grave\u2019s ophthalmopathy. N Engl J Med 362:726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"2332_CR2","doi-asserted-by":"publisher","unstructured":"Lazarus JH, Marino M (2010) Orbit-thyroid relationship. In: Wiersinga WM, Kahaly GJ (eds) Graves\u2019 orbitopathy\u2014a multidisciplinary approach\u2014question and answers. Karger, Basel, pp 26\u201332. https:\/\/doi.org\/10.1159\/000320425","DOI":"10.1159\/000320425"},{"key":"2332_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1089\/thy.2007.0170","volume":"17","author":"B Rapoport","year":"2007","unstructured":"Rapoport B, McLachlan SM (2007) The thyrotropin receptor in Graves\u2019 disease. Thyroid 17:911\u2013922. https:\/\/doi.org\/10.1089\/thy.2007.0170","journal-title":"Thyroid"},{"key":"2332_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340\u20132347. https:\/\/doi.org\/10.1210\/jc.2016-1315","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2016.00167","volume":"7","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Janssen JAMJL (2017) Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol 7:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2016.00167","journal-title":"Front Endocrinol"},{"key":"2332_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107502","volume":"209","author":"CC Krieger","year":"2020","unstructured":"Krieger CC, Neumann S, Gershengorn MC (2020) TSH\/IGF1 receptor crosstalk: mechanism and clinical implications. Pharmacol Ther 209:107502. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107502","journal-title":"Pharmacol Ther"},{"key":"2332_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros P, Heged\u00fcs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Curr\u00f2 N, Konuk O, Marin\u00f2 M, Mitchell AL, Stankovic B, T\u00f6r\u00fcner FB, Von Arx G, Zarkovi\u0107 M, Wiersinga WM (2017) Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:4\u20139. https:\/\/doi.org\/10.1186\/s13023-017-0625-1","journal-title":"Orphanet J Rare Dis"},{"key":"2332_CR8","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"2332_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443\u20131449. https:\/\/doi.org\/10.1210\/jc.2012-3873","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40618-016-0516-7","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L (2016) The phenotype of newly diagnosed Graves\u2019 disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 39:1445\u20131451. https:\/\/doi.org\/10.1007\/s40618-016-0516-7","journal-title":"J Endocrinol Invest"},{"key":"2332_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","volume":"99","author":"P Perros","year":"2015","unstructured":"Perros P, Zarkovi M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Iri S, Daumerie C, Eckstein A, Fichter N, F\u00fchrer D, Heged\u00fcs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Curr\u00f2 N, Dayan C, Dickinson J, Knezevi M, Lane C, Marcocci C, Marin\u00f2 M, M\u00f6ller L, Nardi M, Neoh C, Pearce S, Von Arx G, T\u00f6r\u00fcner FB (2015) PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group on Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99:1531\u20131535. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306733","journal-title":"Br J Ophthalmol"},{"key":"2332_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/bjo-2022-322442","volume":"108","author":"A Schuh","year":"2023","unstructured":"Schuh A, Ayvaz G, Baldeschi L, Bareti\u0107 M, Bechtold D, Boschi A, Brix TH, Burlacu M-C, Ciric J, Covelli D, Curr\u00f2 N, Donati S, Eckstein AK, Fichter N, F\u00fchrer D, Horn M, Jab\u0142o\u0144ska-Pawlak A, Juri Mandi\u0107 J, Kahaly GJ, Konuk O, Langbein A, Lanzolla G, Marcocci C, Marin\u00f2 M, Mi\u015bkiewicz P, Beleslin BN, P\u00e9rez-L\u00e1zaro A, P\u00e9rez-L\u00f3pez M, Ponto KA, Quinn A, Rudofsky G, Salvi M, Schittkowski MP, Tanda ML, Toruner F, Vaidya B, Hintschich CR (2023) Presentation of Graves\u2019 orbitopathy within European Group On Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). Br J Ophthalmol 108:294\u2013300. https:\/\/doi.org\/10.1136\/bjo-2022-322442","journal-title":"Br J Ophthalmol"},{"key":"2332_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena L (2011) The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592\u2013599. https:\/\/doi.org\/10.1210\/jc.2010-2329","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1530\/EJE-18-0039","volume":"178","author":"W Wiersinga","year":"2018","unstructured":"Wiersinga W, \u017darkovi\u0107 M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, Von Arx G, Daumerie C, Christina Burlacu M, Kahaly G, Pitz S, Beleslin B, \u0106iri\u0107 J, Ayvaz G, Konuk O, T\u00f6r\u00f6ner FB, Salvi M, Covelli D, Curro N, Heged\u00f6s L, Brix T (2018) Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism. Eur J Endocrinol 178:635\u2013643. https:\/\/doi.org\/10.1530\/EJE-18-0039","journal-title":"Eur J Endocrinol"},{"key":"2332_CR15","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"Tr\u00e4isk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystr\u00f6m E, Ponjavic V, Taube A, T\u00f6rring O, Wallin G, \u00c5sman P, Lundell G, Lindstedt G, Michanek A, Norrsell K, Valdemarsson S, Garkavij M, Tennvall J, Widmark H, Stigmar G, Arwidi \u00c5, Bjelkengren G, Hemdahl B, J\u00f6nsson H, Becker C, Freyschuss B, Hoffstedt J, Tullgren O, Wahrenberg H, Wennlund A, R\u00f6jdmark S, S\u00e4\u00e4f M, Thor\u00e9n M, Hamberger B, Blomgren H, Hilding C, Hjelm Skog AL (2009) Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700\u20133707. https:\/\/doi.org\/10.1210\/jc.2009-0747","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR16","doi-asserted-by":"publisher","first-page":"302537","DOI":"10.1155\/2012\/302537","volume":"2012","author":"M \u017darkovi\u0107","year":"2012","unstructured":"\u017darkovi\u0107 M (2012) The role of oxidative stress on the pathogenesis of Graves\u2019 disease. J Thyroid Res 2012:302537. https:\/\/doi.org\/10.1155\/2012\/302537","journal-title":"J Thyroid Res"},{"key":"2332_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326. https:\/\/doi.org\/10.1159\/000443828","journal-title":"Eur Thyroid J"},{"key":"2332_CR18","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1210\/jc.2006-1402","volume":"91","author":"N Manji","year":"2006","unstructured":"Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, Lazarus JH, Pearce SHS, Vaidya B, Gough SC, Franklyn JA (2006) Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91:4873\u20134880. https:\/\/doi.org\/10.1210\/jc.2006-1402","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cen.12222","volume":"79","author":"WM Wiersinga","year":"2013","unstructured":"Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145\u2013151. https:\/\/doi.org\/10.1111\/cen.12222","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2332_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell\u2019Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632\u2013635. https:\/\/doi.org\/10.7326\/0003-4819-129-8-199810150-00010","journal-title":"Ann Intern Med"},{"key":"2332_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/jc.2006-1824","volume":"92","author":"TJ Cawood","year":"2007","unstructured":"Cawood TJ, Moriarty P, O\u2019Farrelly C, O\u2019Shea D (2007) Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92:59\u201364. https:\/\/doi.org\/10.1210\/jc.2006-1824","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR22","doi-asserted-by":"publisher","first-page":"4676289","DOI":"10.1155\/2016\/4676289","volume":"2016","author":"HC Kau","year":"2016","unstructured":"Kau HC, Wu SB, Tsai CC, Liu CJL, Wei YH (2016) Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves\u2019 ophthalmopathy. Oxid Med Cell Longev 2016:4676289. https:\/\/doi.org\/10.1155\/2016\/4676289","journal-title":"Oxid Med Cell Longev"},{"key":"2332_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12905-022-01791-1","volume":"22","author":"H Tehrani","year":"2022","unstructured":"Tehrani H, Mahdizadeh M, Peyman N, Gholian-Aval M, Charoghchian Khorasani E, Jafari A (2022) Exploration factors on smoking among female adolescents based on the viewpoints of Iranian adolescent girls. BMC Womens Health 22:1\u20138. https:\/\/doi.org\/10.1186\/s12905-022-01791-1","journal-title":"BMC Womens Health"},{"key":"2332_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.numecd.2015.01.003","volume":"25","author":"R Le Moli","year":"2015","unstructured":"Le Moli R, Muscia V, Tumminia A, Frittitta L, Buscema M, Palermo F, Sciacca L, Squatrito S, Vigneri R (2015) Type 2 diabetic patients with Graves\u2019 disease have more frequent and severe Graves\u2019 orbitopathy. Nutr Metab Cardiovasc Dis 25:452\u2013457. https:\/\/doi.org\/10.1016\/j.numecd.2015.01.003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2332_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00933","volume":"10","author":"G Lanzolla","year":"2020","unstructured":"Lanzolla G, Vannucchi G, Ionni I, Campi I, Sileo F, Lazzaroni E, Marin\u00f2 M (2020) Cholesterol serum levels and use of statins in Graves\u2019 orbitopathy: a new starting point for the therapy. Front Endocrinol 10:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2019.00933","journal-title":"Front Endocrinol"},{"key":"2332_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.609895","volume":"11","author":"A Naselli","year":"2020","unstructured":"Naselli A, Moretti D, Regalbuto C, Arpi ML, Lo Giudice F, Frasca F, Belfiore A, Le Moli R (2020) Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves\u2019 ophthalmopathy to parenteral corticosteroids. Front Endocrinol 11:1\u201310. https:\/\/doi.org\/10.3389\/fendo.2020.609895","journal-title":"Front Endocrinol"},{"key":"2332_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","volume":"45","author":"EJ Neag","year":"2022","unstructured":"Neag EJ, Smith TJ (2022) 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest 45:235\u2013259. https:\/\/doi.org\/10.1007\/s40618-021-01663-9","journal-title":"J Endocrinol Invest"},{"key":"2332_CR28","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/jc.2012-1275","volume":"97","author":"P Laurberg","year":"2012","unstructured":"Laurberg P, Berman DC, Pedersen IB, Andersen S, Carl\u00e9 A (2012) Incidence and clinical presentation of moderate to severe Graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325\u20132332. https:\/\/doi.org\/10.1210\/jc.2012-1275","journal-title":"J Clin Endocrinol Metab"},{"key":"2332_CR29","unstructured":"Olivieri A, Vitti P (2014) Rapporti ISTISAN 14\/6. ISSN, 1123\u20133127"},{"key":"2332_CR30","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1097\/IOP.0000000000001136","volume":"34","author":"M Marin\u00f2","year":"2018","unstructured":"Marin\u00f2 M, Menconi F, Dottore GR, Leo M, Marcocci C (2018) Selenium in Graves hyperthyroidism and orbitopathy. Ophthal Plast Reconstr Surg 34:S105\u2013S110. https:\/\/doi.org\/10.1097\/IOP.0000000000001136","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2332_CR31","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/nejmoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931. https:\/\/doi.org\/10.1056\/nejmoa1012985","journal-title":"N Engl J Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02332-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T07:25:57Z","timestamp":1725261957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02332-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02332-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rosario Le Moli is member of the EUGOGO and contribute as referee for the Journal of Endocrinological Investigation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by Ethics Committee Garibaldi Nesima Hospital\u2014Catania.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}